Cytek Biosciences, Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

CTKB$5.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Three months ended March 31,
(In thousands, except share and per share data)	2025	2024
Revenue, net:
Product	$28,110	$34,122
Service	13,347	10,738
Total revenue, net	41,457	44,860
Cost of sales:
Product	15,529	16,746
Service	5,771	5,101
Total cost of sales	21,300	21,847
Gross profit	20,157	23,013
Operating expenses:
Research and development	9,725	9,796
Sales and marketing	12,509	12,543
General and administrative	12,898	11,408
Total operating expenses	35,132	33,747
Loss from operations	(14,975)	(10,734)
Other income (expense):
Interest expense	(291)	(441)
Interest income	508	1,359
Other income, net	3,492	823
Total other income, net	3,709	1,741
Loss before income taxes	(11,266)	(8,993)
Provision for (benefit from) income taxes	136	(2,824)
Net loss	(11,402)	(6,169)
Net loss, basic and diluted	$(11,402)	$(6,169)
Net loss per share, basic	$(0.09)	$(0.05)
Net loss per share, diluted	$(0.09)	$(0.05)
Weighted-average shares used in calculating net loss per share, basic	128,339,481	130,920,971
Weighted-average shares used in calculating net loss per share, diluted	128,339,481	130,920,971
Comprehensive loss:
Net loss	$(11,402)	$(6,169)
Foreign currency translation adjustment, net of tax	(560)	(244)
Unrealized loss on marketable securities	(65)	(35)
Net comprehensive loss	$(12,027)	$(6,448)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.